Abstract: A method is provided for producing a population of post-mitotic cells of the neutrophil lineage, which method comprises the ex vivo steps of: (a) providing a population of cells comprising neutrophil progenitor cells; and (b) culturing the population of cells in an animal cell culture medium comprising (i) one or more early acting cytokines and (ii) one or more cytokines that differentiate said progenitor cells into a neutrophil specific lineage, under conditions of low oxidative stress, the culture medium being agitated when the cells are at a cell density at which oxygen transfer via the surface of the culture medium is insufficient for growth of the progenitor cells and the progeny thereof under static conditions, to produce a population of post-mitotic cells of the neutrophil lineage. The resulting population of cells can be used to increase the number of neutrophils in a patient.
Type:
Grant
Filed:
July 23, 2007
Date of Patent:
May 8, 2012
Assignee:
The University of Queensland
Inventors:
Lars K. Nielsen, Emma L. Palfreyman, Nicholas E. Timmins
Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.
Type:
Grant
Filed:
July 1, 2011
Date of Patent:
April 17, 2012
Assignee:
Crucell Switzerland AG
Inventors:
Martin A. Billeter, Pius Spielhofer, Karin Kalin, Frank Radecke, Henriette Schneider
Abstract: A method of delivering cardiac stem cell and treating damaged cardiac tissue is provided. The method involves isolation of subject's cardiac circulation from the subject's systemic circulation and perfusing a solution comprising stem cells into the cardiac circuit.
Type:
Grant
Filed:
December 4, 2006
Date of Patent:
April 17, 2012
Assignee:
The Trustees of the University of Pennsylvania
Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.
Abstract: This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.
Abstract: The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.
Type:
Grant
Filed:
October 20, 2010
Date of Patent:
February 28, 2012
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
David M. Stern, Ann Marie Schmidt, Shi Du Yan
Abstract: The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
Abstract: Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-? (A?) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
September 20, 2011
Assignee:
The University of Zurich
Inventors:
Jan Grimm, Roger Nitsch, Marlen Knobloch, Uwe Konietzko, Markus Rudin, Thomas Müggler, Felicitas Kranz
Abstract: This invention provides novel animal models for a human pathogen that is capable of exhibiting analogous secondary disease manifestation. Other animal models for a human pathogen are provided by this invention which are capable of exhibiting analogous secondary disease manifestations and are also capable of responding to therapeutic or preventive measures to such secondary disease manifestations. Other animal models for human retrovirus infections are provided including lower primates and primate excluding any members of the order Anthropoidea. Compositions, drugs, products and procedures for therapeutic and diagnostic applications derived from the animal models of this invention are also described and provided.
Type:
Grant
Filed:
December 12, 2001
Date of Patent:
September 6, 2011
Assignee:
Enzo Therapeutics, Inc.
Inventors:
Jennifer June Brown, Elazar Rabbani, James J. Donegan, Jayanta Roy-Chowdhury
Abstract: The subject invention pertains to nucleic acid constructs for post-transcriptional control of expression of a polynucleotide encoding a protein in a cell, wherein the constructs include a metabolite responsive instability element such as the glucose-regulated mRNA instability element. The subject invention further pertains to host cells and vectors comprising the nucleic acid constructs of the invention, as well as probes, methods, and kits for detecting metabolite responsive instability elements or mutations thereof. The present invention further concerns a reporter vector useful for detecting intracellular glucose and glucose-analogs, host cells genetically modified with the reporter vector, and methods for detecting intracellular glucose. The present invention utilizes an element that regulates messenger RNA (mRNA) stability in response to a metabolite such as glucose or a glucose analog.
Abstract: Human TAOJIK genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of TAOJIK are provided.
Type:
Grant
Filed:
December 12, 2002
Date of Patent:
August 23, 2011
Assignee:
Exelixis, Inc.
Inventors:
Michael A. Costa, Steven Brian Gendreau, Emery G. Dora, III, Monique Nicoll, Lenore Urbani, Jeffrey S. Larson
Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.
Type:
Grant
Filed:
September 6, 2007
Date of Patent:
August 9, 2011
Assignee:
Crucell Switzerland AG
Inventors:
Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
Abstract: The invention relates to isolated and purified neural precursor cells, to methods for the generation of such precursor cells in unlimited quantities from embryonic stem cells, and to their use for the therapy of neural defects, particularly in mammals, preferably in human beings, and for the generation of polypeptides.
Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the hippocampus, subthalamic nucleus of the basal ganglia, mesaphilia and thalamus.
Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. Specifically, the present invention relates to expression of hepsin protease. The detected proteases are themselves specifically over-expressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.
Type:
Grant
Filed:
April 30, 2002
Date of Patent:
May 3, 2011
Assignee:
Board of Trustees of the University of Arkansas
Inventors:
Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin
Abstract: A method of treating or preventing development of a neurological disorder has been developed wherein a subject with the disorder, or at risk of developing a disorder, is vaccinated against a brain protein or antigen. Alternatively, the antibodies can be directly administered to the individual in need of treatment thereof. Animal studies demonstrate potent efficacy in the treatment of epilepsy, stroke and cognition in animal models vaccinated against the NMDA receptor.
Abstract: The present invention relates to a method for preparing a modified folded protein, comprising modifying unfolded a-chains comprising a collagenous amino acid sequence and thereafter folding at least part of the modified a-chains into a quaternary protein structure, in particular a helical protein structure. The invention allows for an attractive alternative for making recombinant proteins, such as recombinant collagens and the like, which may be used in a variety of biomedical and other applications.
Type:
Grant
Filed:
April 7, 2005
Date of Patent:
April 26, 2011
Assignee:
Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek TNO
Inventors:
Rudolf Antonius Bank, Anne-Marie Zuurmond, Johannes Petrus M. Jore, Cornelius Antonius M. J. J. van den Hondel
Abstract: Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration.
Type:
Grant
Filed:
March 23, 2009
Date of Patent:
April 19, 2011
Assignee:
University of Kentucky Research Foundation
Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.
Type:
Grant
Filed:
June 5, 2001
Date of Patent:
April 5, 2011
Assignee:
Sanford-Burnham Medical Research Institute
Abstract: The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.
Type:
Grant
Filed:
August 14, 2000
Date of Patent:
April 5, 2011
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
David M. Stern, Ann Marie Schmidt, Shi Du Yan